NASDAQ:CELG - Celgene Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$79.54 +1.88 (+2.42 %)
(As of 05/25/2018 01:15 AM ET)
Previous Close$77.66
Today's Range$78.51 - $79.89
52-Week Range$74.13 - $147.17
Volume8.48 million shs
Average Volume7.64 million shs
Market Capitalization$55.53 billion
P/E Ratio11.63
Dividend YieldN/A
Beta1.49

About Celgene (NASDAQ:CELG)

Celgene logoCelgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. to advance a PD-1 Inhibitor program for solid tumor cancers. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; and Prothena Corporation plc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CELG
CUSIP15102010
Phone908-673-9000

Debt

Debt-to-Equity Ratio3.92
Current Ratio2.53
Quick Ratio2.36

Price-To-Earnings

Trailing P/E Ratio11.63
Forward P/E Ratio10.42
P/E Growth0.48

Sales & Book Value

Annual Sales$13.00 billion
Price / Sales4.43
Cash Flow$7.9066 per share
Price / Cash10.06
Book Value$7.14 per share
Price / Book11.14

Profitability

EPS (Most Recent Fiscal Year)$6.84
Net Income$2.94 billion
Net Margins20.73%
Return on Equity72.92%
Return on Assets17.48%

Miscellaneous

Employees7,467
Outstanding Shares724,830,000

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Celgene's stock split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were payable to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene announced that its Board of Directors has initiated a share repurchase plan on Thursday, May 24th 2018, which authorizes the company to buyback $3,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 5.4% of its shares through open market purchases. Shares buyback plans are often an indication that the company's board believes its shares are undervalued.

How were Celgene's earnings last quarter?

Celgene (NASDAQ:CELG) issued its quarterly earnings results on Friday, May, 4th. The biopharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.09. The biopharmaceutical company earned $3.54 billion during the quarter, compared to analysts' expectations of $3.47 billion. Celgene had a net margin of 20.73% and a return on equity of 72.92%. The firm's quarterly revenue was up 19.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.68 EPS. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene updated its FY18 earnings guidance on Friday, May, 4th. The company provided EPS guidance of $8.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.45. The company issued revenue guidance of $14.8 billion, compared to the consensus revenue estimate of $14.81 billion.

What price target have analysts set for CELG?

32 brokers have issued twelve-month target prices for Celgene's stock. Their predictions range from $85.00 to $166.00. On average, they anticipate Celgene's stock price to reach $124.4893 in the next year. View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:
  • 1. According to Zacks Investment Research, "Celgene’s first-quarter results were encouraging as the company beat on both sales and earnings. Revlimid sales were impressive yet again along with Pomalyst and Otezla. Celgene’s key growth driver, Revlimid, continues to drive revenues. However, a late stage study on Revlimid in combination with Rituxan failed. Celgene suffered yet another setback when it received Refusal to File letter from the FDA regarding its New Drug Application for multiple sclerosis candidate ozanimod. Celgene was on the look-out of new deals and acquisitions given a lacklustre 2017 and the Juno acquisition was on the same track. We are positive on the acquisition. The bluebird deal will further bolster Celgene’s presence in the CAR-T space. The company has a few data read-outs lined up for the rest of the year on key drugs. Shares have underperformed the industry in the last six months." (5/10/2018)
  • 2. Cann analysts commented, "Celgene announced today that John Weiland has been elected to its board of directors. Mr. Weiland was most recently President and Chief Operating Officer of C.R. Bard, Inc. Prior to this role, Mr. Weiland held the position of Group President of Bard and had global responsibility for Bard Medical Division, Bard Urological Division, Davol Inc., Bard Endoscopic Technologies Division and Bard’s Worldwide Manufacturing Operations. We believe Mr. Weiland will bring significant commercial and operational experience to the Celgene Board." (2/15/2018)
  • 3. Cantor Fitzgerald analysts commented, "CELG’s current CEO, Mark Alles, will assume the role of Chairman of the Board, following the retirement of current COB Robert Hugin, effective February 5th, which follows his departure as President in early 2016." (1/29/2018)

Are investors shorting Celgene?

Celgene saw a drop in short interest in May. As of May 15th, there was short interest totalling 12,301,961 shares, a drop of 11.0% from the April 30th total of 13,818,817 shares. Based on an average trading volume of 6,863,540 shares, the short-interest ratio is presently 1.8 days. Approximately 1.6% of the shares of the company are sold short.

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 59)
  • Mr. Peter N. Kellogg BSE, MBA, Exec. VP, CFO & Chief Accounting Officer (Age 62)
  • Mr. Rupert J. Vessey, Exec. VP and Pres of Research & Early Devel. (Age 53)
  • Mr. Patrick E. Flanigan III, Corp. VP of Investor Relations
  • Mr. Gerald F. Masoudi, Exec. VP, Gen. Counsel & Corp. Sec. (Age 50)

Has Celgene been receiving favorable news coverage?

Media stories about CELG stock have trended positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Celgene earned a coverage optimism score of 0.42 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Celgene's major shareholders?

Celgene's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.51%), Edgewood Management LLC (1.65%), Northern Trust Corp (1.33%), Franklin Resources Inc. (1.28%), American Century Companies Inc. (0.60%) and Legal & General Group Plc (0.49%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Mark J Alles, Michael A Friedman, Michael D Casey, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Which major investors are selling Celgene stock?

CELG stock was sold by a variety of institutional investors in the last quarter, including Polen Capital Management LLC, Carmignac Gestion, Massachusetts Financial Services Co. MA, Franklin Resources Inc., Northern Trust Corp, OppenheimerFunds Inc., Eaton Vance Management and Atlantic Trust Group LLC. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Insider Buying and Selling for Celgene.

Which major investors are buying Celgene stock?

CELG stock was purchased by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., Natixis, Edgewood Management LLC, Westfield Capital Management Co. LP, Commerzbank Aktiengesellschaft FI, Mackay Shields LLC, American Century Companies Inc. and Darrell & King LLC. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene and Mark J Alles. View Insider Buying and Selling for Celgene.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $79.54.

How big of a company is Celgene?

Celgene has a market capitalization of $55.53 billion and generates $13.00 billion in revenue each year. The biopharmaceutical company earns $2.94 billion in net income (profit) each year or $6.84 on an earnings per share basis. Celgene employs 7,467 workers across the globe.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]


MarketBeat Community Rating for Celgene (CELG)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  1,752 (Vote Outperform)
Underperform Votes:  562 (Vote Underperform)
Total Votes:  2,314
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celgene (NASDAQ:CELG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
32 Wall Street analysts have issued ratings and price targets for Celgene in the last 12 months. Their average twelve-month price target is $124.4893, suggesting that the stock has a possible upside of 56.51%. The high price target for CELG is $166.00 and the low price target for CELG is $85.00. There are currently 1 sell rating, 12 hold ratings and 19 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.562.582.612.67
Ratings Breakdown: 1 Sell Rating(s)
12 Hold Rating(s)
19 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
12 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
18 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
19 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $124.4893$126.4536$129.9893$138.9893
Price Target Upside: 56.51% upside38.81% upside37.72% upside33.00% upside

Celgene (NASDAQ:CELG) Consensus Price Target History

Price Target History for Celgene (NASDAQ:CELG)

Celgene (NASDAQ:CELG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018ArgusDowngradeBuy ➝ HoldLowView Rating Details
5/23/2018Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$102.00LowView Rating Details
5/7/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$93.00 ➝ $90.00LowView Rating Details
5/7/2018Leerink SwannReiterated RatingBuy$123.00 ➝ $115.00MediumView Rating Details
5/7/2018Royal Bank of CanadaDowngradeTop Pick ➝ Outperform$120.00HighView Rating Details
5/6/2018BarclaysSet Price TargetBuy$107.00MediumView Rating Details
5/5/2018Cantor FitzgeraldSet Price TargetHold$112.00MediumView Rating Details
5/5/2018Credit Suisse GroupSet Price TargetBuy$129.00MediumView Rating Details
4/30/2018Evercore ISIReiterated RatingBuyLowView Rating Details
3/26/2018Goldman Sachs GroupLower Price TargetSell ➝ Sell$97.00 ➝ $85.00LowView Rating Details
3/21/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$110.00LowView Rating Details
3/1/2018Robert W. BairdReiterated RatingHold$92.00MediumView Rating Details
2/28/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$144.00 ➝ $139.00HighView Rating Details
2/28/2018William BlairReiterated RatingBuyHighView Rating Details
2/28/2018UBSSet Price TargetBuy$106.00HighView Rating Details
2/28/2018Stifel NicolausReiterated RatingBuy ➝ Buy$130.00 ➝ $128.00HighView Rating Details
2/28/2018SunTrust BanksDowngradeBuy ➝ Hold$139.00 ➝ $106.00HighView Rating Details
2/15/2018CannReiterated RatingBuy$163.00LowView Rating Details
2/4/2018MizuhoReiterated RatingBuy$128.00HighView Rating Details
1/23/2018BTIG ResearchReiterated RatingHoldMediumView Rating Details
1/18/2018Piper Jaffray CompaniesReiterated RatingHold$104.00LowView Rating Details
1/10/2018GuggenheimReiterated RatingBuy$147.00LowView Rating Details
1/8/2018Deutsche BankSet Price TargetHold$110.00LowView Rating Details
1/8/2018OppenheimerSet Price TargetBuy$166.00HighView Rating Details
1/5/2018Bank of AmericaDowngradeBuy ➝ Neutral$104.68 ➝ $120.00MediumView Rating Details
12/22/2017CitigroupReiterated RatingHoldMediumView Rating Details
12/8/2017Atlantic SecuritiesUpgradeNeutral ➝ OverweightHighView Rating Details
11/16/2017Canaccord GenuitySet Price TargetBuy$140.00N/AView Rating Details
10/27/2017JMP SecuritiesDowngradeOutperform ➝ Market PerformN/AView Rating Details
10/26/2017Wells Fargo & CoDowngradeOutperform ➝ Market PerformN/AView Rating Details
10/16/2017Jefferies GroupReiterated RatingBuy$160.00N/AView Rating Details
9/12/2017CowenReiterated RatingBuy$150.00LowView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy ➝ HoldN/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Celgene (NASDAQ:CELG) Earnings History and Estimates Chart

Earnings by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ:CELG) Earnings Estimates

2018 EPS Consensus Estimate: $7.68
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.77$1.77$1.77
Q2 20182$1.87$1.87$1.87
Q3 20182$1.96$1.99$1.98
Q4 20182$2.06$2.06$2.06

Celgene (NASDAQ CELG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018$2.10N/AView Earnings Details
5/4/2018Q1 2018$1.96$2.05$3.4663 billion$3.5380 billionViewN/AView Earnings Details
1/25/2018Q4 2017$1.78$1.87$3.4645 billion$3.4830 billionViewListenView Earnings Details
10/26/2017Q3 2017$1.87$1.91$3.4167 billion$3.2870 billionViewN/AView Earnings Details
7/27/20176/30/2017$1.61$1.82$3.2324 billion$3.2680 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.47$1.68$3.0367 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.9830 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
10/28/2010Q3 2010$0.32$0.32ViewN/AView Earnings Details
7/29/2010Q2 2010$0.30$0.30ViewN/AView Earnings Details
4/29/2010Q1 2010$0.28$0.27ViewN/AView Earnings Details
1/28/2010Q4 2009$0.29$0.29ViewN/AView Earnings Details
10/22/2009Q3 2009$0.25$0.25ViewN/AView Earnings Details
7/23/2009Q2 2009$0.21$0.20ViewN/AView Earnings Details
4/30/2009Q1 2009$0.20$0.16ViewN/AView Earnings Details
1/29/2009Q4 2008$0.19$0.19ViewN/AView Earnings Details
10/23/2008Q3 2008$0.18$0.17ViewN/AView Earnings Details
7/24/2008Q2 2008$0.16$0.15ViewN/AView Earnings Details
5/8/2008Q1 2008$0.16$0.17ViewN/AView Earnings Details
1/31/2008Q4 2007$0.15$0.15ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Celgene (NASDAQ:CELG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Celgene (NASDAQ CELG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 75.69%
Insider Trading History for Celgene (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ CELG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2018Gilla KaplanDirectorSell27,750$78.66$2,182,815.00View SEC Filing  
5/9/2018Mark J AllesCEOBuy1,208$82.60$99,780.80187,316View SEC Filing  
3/12/2018James J LoughlinDirectorSell9,250$92.01$851,092.50View SEC Filing  
2/23/2018Ernest MarioDirectorSell13,370$94.49$1,263,331.30View SEC Filing  
2/20/2018Gilla KaplanDirectorSell9,250$94.83$877,177.5094,801View SEC Filing  
2/15/2018Gilla KaplanDirectorSell9,250$95.99$887,907.5094,801View SEC Filing  
2/8/2018Mark J AllesInsiderBuy3,260$91.90$299,594.00178,904View SEC Filing  
9/25/2017Terrie CurranInsiderSell1,727$143.89$248,498.033,925View SEC Filing  
9/12/2017Gilla KaplanDirectorSell9,250$141.56$1,309,430.0085,551View SEC Filing  
9/5/2017Michael D CaseyDirectorSell9,250$139.03$1,286,027.509,250View SEC Filing  
8/10/2017Ernest MarioDirectorSell18,506$130.52$2,415,403.1269,424View SEC Filing  
8/2/2017Gilla KaplanDirectorSell7,500$134.52$1,008,900.0076,301View SEC Filing  
6/26/2017James J LoughlinDirectorSell18,500$133.57$2,471,045.0032,877View SEC Filing  
6/22/2017Michael A FriedmanDirectorSell10,000$132.50$1,325,000.005,000View SEC Filing  
6/22/2017Robert J HuginInsiderSell175,970$134.14$23,604,615.801,033,909View SEC Filing  
6/21/2017Michael D CaseyDirectorSell9,250$133.05$1,230,712.509,250View SEC Filing  
6/19/2017Michael D. CaseyDirectorSell9,250$125.59$1,161,707.50View SEC Filing  
6/15/2017Rupert VesseyInsiderSell4,785$120.18$575,061.304,004View SEC Filing  
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.0032,169View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.3973,109View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00778View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.0018,600View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.5650,000View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.0031,332View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.4072,142View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.0042,919View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.001,022,201View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.001,122,201View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.2872,518View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.0019,785View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.0082,449View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.6888,485View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.0088,485View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.1625,705View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00100,671View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.7850View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.0022,688View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.7815,349View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celgene (NASDAQ CELG) News Headlines

Source:
DateHeadline
$100,000 Threshold: Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Celgene Corporation Investors (CELG)$100,000 Threshold: Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Celgene Corporation Investors (CELG)
feeds.benzinga.com - May 24 at 9:33 PM
Celgenes Buybacks Are Coming Up EmptyCelgene's Buybacks Are Coming Up Empty
www.wsj.com - May 24 at 3:49 PM
Celgene Corporation -- Moodys: Celgenes accelerated share repurchase credit negativeCelgene Corporation -- Moody's: Celgene's accelerated share repurchase credit negative
finance.yahoo.com - May 24 at 3:49 PM
[$$] Celgenes Buybacks Are Coming Up Empty[$$] Celgene's Buybacks Are Coming Up Empty
finance.yahoo.com - May 24 at 3:49 PM
Celgene (CELG) to Buyback $3.00 billion in  Outstanding Stock Celgene (CELG) to Buyback $3.00 billion in Outstanding Stock
www.americanbankingnews.com - May 24 at 11:28 AM
Form 8-K CELGENE CORP /DE/ For: May 24Form 8-K CELGENE CORP /DE/ For: May 24
www.streetinsider.com - May 24 at 10:33 AM
Morning Movers: Best Buy Bumbles; Celgene ClimbsMorning Movers: Best Buy Bumbles; Celgene Climbs
www.barrons.com - May 24 at 10:33 AM
Celgene shares jump 1.2% premarket on news of additional $3 billion share buybackCelgene shares jump 1.2% premarket on news of additional $3 billion share buyback
www.marketwatch.com - May 24 at 10:33 AM
David's 5 Winning Stocks for a Thinking World: 2 Years Later, Has a Bet on Brains Paid Off?David's 5 Winning Stocks for a Thinking World: 2 Years Later, Has a Bet on Brains Paid Off?
finance.yahoo.com - May 23 at 3:46 PM
Celgene Wins One Bull, Loses Another On Revlimid PotentialCelgene Wins One Bull, Loses Another On Revlimid Potential
finance.yahoo.com - May 23 at 3:46 PM
Celgene Cratering to Four-Year Low Leaves Analysts SplitCelgene Cratering to Four-Year Low Leaves Analysts Split
finance.yahoo.com - May 23 at 3:46 PM
CELG EQUITY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018CELG EQUITY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018
finance.yahoo.com - May 23 at 3:46 PM
Analysts Split: Celgene Tilts 'To Greater Risk' On Revlimid ChallengesAnalysts Split: Celgene Tilts 'To Greater Risk' On Revlimid Challenges
finance.yahoo.com - May 23 at 3:46 PM
Celgene (CELG) Downgraded by Argus to "Hold"Celgene (CELG) Downgraded by Argus to "Hold"
www.americanbankingnews.com - May 23 at 12:45 PM
Celgene (CELG) Lifted to Outperform at Sanford C. BernsteinCelgene (CELG) Lifted to Outperform at Sanford C. Bernstein
www.americanbankingnews.com - May 23 at 12:45 PM
UPDATE: Bernstein Upgrades Celgene (CELG) to OutperformUPDATE: Bernstein Upgrades Celgene (CELG) to Outperform
www.streetinsider.com - May 23 at 9:55 AM
Bernstein Upgrades Celgene (CELG) to OutperformBernstein Upgrades Celgene (CELG) to Outperform
www.streetinsider.com - May 23 at 9:55 AM
Is Celgenes Stock A Buy The Dip Opportunity?Is Celgene's Stock A Buy The Dip Opportunity?
seekingalpha.com - May 23 at 9:55 AM
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Celgene Corporation To Contact The FirmLEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Celgene Corporation To Contact The Firm
finance.yahoo.com - May 23 at 9:55 AM
Warren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove ItWarren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove It
finance.yahoo.com - May 23 at 9:55 AM
The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Celgene Corporation (CELG)The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Celgene Corporation (CELG)
finance.yahoo.com - May 23 at 9:55 AM
Celgene Corporation: How to Effectively Buy Into CELG StockCelgene Corporation: How to Effectively Buy Into CELG Stock
investorplace.com - May 22 at 1:57 PM
Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action ...Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action ...
www.businesswire.com - May 22 at 10:08 AM
Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018
www.businesswire.com - May 22 at 10:08 AM
Celgene, Campbells Soup Drop into Mondays 52-Week Low ClubCelgene, Campbell's Soup Drop into Monday's 52-Week Low Club
247wallst.com - May 22 at 10:08 AM
Celgene Strikes Strategic Partnership With EvotecCelgene Strikes Strategic Partnership With Evotec
www.investopedia.com - May 22 at 10:08 AM
Celgene (CELG) Director Gilla Kaplan Sells 27,750 SharesCelgene (CELG) Director Gilla Kaplan Sells 27,750 Shares
www.americanbankingnews.com - May 21 at 7:18 PM
US STOCKS ON THE MOVE-Wabtec, Celgene, Snap, Boxlight, steel stocksUS STOCKS ON THE MOVE-Wabtec, Celgene, Snap, Boxlight, steel stocks
www.nasdaq.com - May 21 at 3:42 PM
Celgene Plunges On Report Its Head Of Mergers Quietly Exited In AprilCelgene Plunges On Report Its Head Of Mergers Quietly Exited In April
finance.yahoo.com - May 21 at 3:42 PM
Celgene business development chief out last monthCelgene business development chief out last month
seekingalpha.com - May 21 at 1:37 PM
Will Public Shaming Sink Celgene?Will 'Public Shaming' Sink Celgene?
seekingalpha.com - May 21 at 10:18 AM
Did Celgene Corporation’s (NASDAQ:CELG) Recent Earnings Growth Beat The Trend?Did Celgene Corporation’s (NASDAQ:CELG) Recent Earnings Growth Beat The Trend?
finance.yahoo.com - May 21 at 10:18 AM
Campbell Soup, Celgene Stumble into Fridays 52-Week Low ClubCampbell Soup, Celgene Stumble into Friday's 52-Week Low Club
247wallst.com - May 19 at 10:12 AM
Call buyers look for Celgene to turn aroundCall buyers look for Celgene to turn around
www.nasdaq.com - May 18 at 3:49 PM
Celgene (CELG) CEO Mark J. Alles Purchases 1,208 SharesCelgene (CELG) CEO Mark J. Alles Purchases 1,208 Shares
www.americanbankingnews.com - May 17 at 5:17 PM
The Punching Bag of Biotech Absorbs More BlowsThe Punching Bag of Biotech Absorbs More Blows
www.bloomberg.com - May 17 at 3:44 PM
Nohla Therapeutics closes $45 million funding round to continue clinical trialsNohla Therapeutics closes $45 million funding round to continue clinical trials
finance.yahoo.com - May 17 at 3:44 PM
Celgene (CELG) Receives Average Recommendation of "Buy" from AnalystsCelgene (CELG) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 17 at 3:35 PM
US Names Drugmakers Gaming Safety System to Shield ProfitsUS Names Drugmakers 'Gaming' Safety System to Shield Profits
www.bloomberg.com - May 17 at 10:37 AM
Celgene (CELG) option implied volatility, to present new blood cancer, solid tumor clinical data at ASCOCelgene (CELG) option implied volatility, to present new blood cancer, solid tumor clinical data at ASCO
www.streetinsider.com - May 17 at 10:37 AM
Celgene (CELG) to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at ASCOCelgene (CELG) to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at ASCO
www.streetinsider.com - May 17 at 10:37 AM
Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of ...Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of ...
www.businesswire.com - May 17 at 10:37 AM
Celgenes (CELG) Management Presents at Bank of America Merrill Lynch Healthcare Conference (Transcript)Celgene's (CELG) Management Presents at Bank of America Merrill Lynch Healthcare Conference (Transcript)
seekingalpha.com - May 17 at 10:37 AM
Generic Revlimid Could Sink CelgeneGeneric Revlimid Could Sink Celgene
seekingalpha.com - May 17 at 10:37 AM
FDA names drugmakers likely blocking access to drug samplesFDA names drugmakers likely blocking access to drug samples
finance.yahoo.com - May 17 at 10:37 AM
$3.68 Billion in Sales Expected for Celgene (CELG) This Quarter$3.68 Billion in Sales Expected for Celgene (CELG) This Quarter
www.americanbankingnews.com - May 17 at 2:38 AM
INVESTOR ALERT: The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG)INVESTOR ALERT: The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG)
finance.yahoo.com - May 16 at 3:48 PM
Hagens Berman Reminds Investors in Celgene Corporation (CELG) of the May 29, 2018 Securities Class Action Lead ...Hagens Berman Reminds Investors in Celgene Corporation (CELG) of the May 29, 2018 Securities Class Action Lead ...
www.prnewswire.com - May 16 at 10:59 AM
Hagens Berman Reminds Investors in Celgene Corporation (CELG) of the May 29, 2018 Securities Class Action Lead Plaintiff DeadlineHagens Berman Reminds Investors in Celgene Corporation (CELG) of the May 29, 2018 Securities Class Action Lead Plaintiff Deadline
finance.yahoo.com - May 16 at 10:59 AM
Todays Research Reports on Trending Tickers: Celgene and Valeant PharmaceuticalsToday's Research Reports on Trending Tickers: Celgene and Valeant Pharmaceuticals
finance.yahoo.com - May 16 at 10:59 AM

SEC Filings

Celgene (NASDAQ:CELG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celgene (NASDAQ:CELG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celgene (NASDAQ CELG) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.